UCB Inspired by patients.Driven by science.Jean-Christophe Tellier, CEO

38th Annual J.P. Morgan Healthcare ConferenceJanuary 15th, 2020 – San Francisco, CA

Disclaimer and safe harbor 2

Forward-looking statementsThis presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”,“plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward-looking statements are based on current plans, estimates andbeliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks,uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materiallydifferent from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability toobtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes inthe prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims,competition from other products including biosimilars, challenges to patent protection for products or product candidates, changes in laws or regulations, exchangerate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is no guarantee that newproduct candidates will be discovered or identified, nor that such product candidates in the pipeline will progress to product approval or that new indications forexisting products will be developed and approved. Preclinical results also do not guarantee safe and effective performance of product candidates in humans.Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners ormay not be as safe or effective as UCB believed at the time of entering into such relationship. Also, UCB or others could discover safety, side effects ormanufacturing problems with its products after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicatean entire class of products may have a material adverse effect on sales of the affected products. Moreover, sales may be impacted by international and domestictrends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny and the reimbursement policies imposed bythird-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Finally, a breakdown, cyberattack or information security breachcould compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are madeonly as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect anychange in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement isrequired pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

3

ality & Assurance Summit 2017

Bringing Cimzia®, Vimpat®, Keppra®, Briviact® & Neupro® to more than 3 million patients

Investing more than 25% of revenue in R&D –above industry average

Committed to driving positive change in society and minimizing our environmental footprint

Profitable growth for the 5th year in a row: € 4.6 billion revenue€ 1.4 billion recurring EBITDA (2018)

We are UCB

We are ~7 500 employees focused on creating value for patients

now and into the future

UCB‘s Patient Value Strategy 4

• To be the Patient Preferred Biopharma Leader

• To bring Differentiated Solutions with Unique Outcomes

• Creating the best individual Experience

• Impact Specific Patient Populations by 2025.

• We are committed to create value for patients, our employees, society and our shareholders.

Mariana, living with epilepsy

UCB is progressing on its strategic growth path 5

2019: Entering the "Accelerate & Expand" phase

Grow & Prepare2015-2018

Accelerate & Expand2019-2021

Breakthrough & Lead2022-2025

• Core products growth

• Briviact® and romosozumablaunch prepared

• Enhanced financials and strategic flexibility

• Maximize the number of lives we can positively impact

• Focus on patients that can benefit most• Strengthen our R&D to deliver new

compounds in shorter cycle time• Identify & act on potential opportunities

• Bring highly differentiated solutions to patients, with high predictability of response

• Be present and lead in specific patient sub-populations by 2025

Outlook and commitment as of JPM 2019 1/2with strong delivery in 2019…

6

• Continued net sales growth of core products Cimzia®, Vimpat®, Keppra®, Briviact® and Neupro® +13% HY 2019 Cimzia® reaching out to nr AxSpA patients in the U.S. - first and only FDA

approved Cimzia® approved and launched in China, approved in Japan

Use financial & strategic flexibility to complement pipeline Agreement to acquire Ra Pharma

• FY 2019 outlook updated – FY results report on February 20, 2020 revenue approx. € 4.9 bn; rEBITDA ratio at least at the upper end of 27-29%*

nr AxSpA : non-radiographic axial spondyloarthitis * unaudited financials

Outlook and commitment as of JPM 2019 2/2with significant progress in 2019…

7

Evenity® • severe osteoporosis Launched in Japan, U.S. and Canada, approved in EU and several countries

Nayzilam® • acute repetitive epilepsy seizures Launched in the U.S.

bimekizumab• psoriasis (PsO)

• psoriatic arthritis (PsA)• axial spondyloarthritis (axSpA)

• 3 Positive Phase 3 trials, submission mid-2020• Phase 3 started, results end of 2021• Phase 3 started, results end of 2021

padsevonil • drug-resistant epilepsy • Phase 2b topline results H1 2020• Phase 3 started, topline results H2 2021

rozanolixizumab• myasthenia gravis (MG)• immune thrombocytopenia (ITP)• CIDP*

• Phase 3 started, results H1 2021• Phase 3 to start Q1 2020• Phase 2a started, results H1 2021

UCB0107 • progressive supranuclear palsy • Positive phase 1 results • Confirmatory Phase to start Q2 2020

Evenity in partnership with Amgen globally* chronic inflammatory demylinating polyneuropathy

6 potential product launches by 2025

Ra Pharma, an excellent strategic fit with UCB 8

Enriching our pipeline, adding new patient populations

• Acquiring novel, potential best-in-class C5 targeting molecule

• Addressing significant unmet medical need in gMG, IMNM, ALS and other disorders

• Highly complementary with rozanolixizumab to support patients across their individual journey through moderate/severe chronic and acute settings

• Long term innovation acceleration with addition of proprietary ExtremeDiversity™ macrocyclic peptide chemistry platform

gMG : generalized myasthenia gravisIMNM: immune-mediated necrotizing myopathyALS: amyotrophic lateral sclerosis.

Creating value for patients

now and into the future

Transaction expected to close by the end of Q1 2020.

UCB is progressing on its strategic growth path 9

2019: Entering the "Accelerate & Expand" phase

* Ra Pharma transaction: closing expected by end of Q1 2020

Grow & Prepare2015-2018

Accelerate & Expand2019-2021

Breakthrough & Lead2022-2025

• Core products growth

• Briviact® and romosozumablaunch prepared

• Enhanced financials and strategic flexibility

• Maximize the number of lives we can positively impact

• Focus on patients that can benefit most• Strengthen our R&D to deliver new

compounds in shorter cycle time• Identify & act on potential opportunities

• Bring highly differentiated solutions to patients, with high predictability of response

• Be present and lead in specific patient sub-populations by 2025

6/7* potential product launches in the next 5 years

10

Creating value for patients, employees, society and

shareholders

Haneke, living with osteoporosis

Jie, living with epilepsy

Sustainable Patient Value Strategy

Thank you

11